Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

174 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods.
Fukui T, Rahman M, Hayashi K, Takeda K, Higaki J, Sato T, Fukushima M, Sakamoto J, Morita S, Ogihara T, Fukiyama K, Fujishima M, Saruta T; CASE-J Study Group. Fukui T, et al. Among authors: fukiyama k. Hypertens Res. 2003 Dec;26(12):979-90. doi: 10.1291/hypres.26.979. Hypertens Res. 2003. PMID: 14717341 Free article. Review.
Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial.
Ogihara T, Nakao K, Fukui T, Fukiyama K, Ueshima K, Oba K, Sato T, Saruta T; Candesartan Antihypertensive Survival Evaluation in Japan Trial Group. Ogihara T, et al. Among authors: fukiyama k. Hypertension. 2008 Feb;51(2):393-8. doi: 10.1161/HYPERTENSIONAHA.107.098475. Epub 2008 Jan 2. Hypertension. 2008. PMID: 18172059 Clinical Trial.
The optimal target blood pressure for antihypertensive treatment in Japanese elderly patients with high-risk hypertension: a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial.
Ogihara T, Nakao K, Fukui T, Fukiyama K, Fujimoto A, Ueshima K, Oba K, Shimamoto K, Matsuoka H, Saruta T; CASE-J Trial Group. Ogihara T, et al. Among authors: fukiyama k. Hypertens Res. 2008 Aug;31(8):1595-601. doi: 10.1291/hypres.31.1595. Hypertens Res. 2008. PMID: 18971535
Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex).
Ogihara T, Ueshima K, Nakao K, Fukiyama K, Oba K, Yasuno S, Fujimoto A, Sato T, Matsuoka H, Saruta T; CASE-J Ex Study Group. Ogihara T, et al. Among authors: fukiyama k. Hypertens Res. 2011 Dec;34(12):1295-301. doi: 10.1038/hr.2011.120. Epub 2011 Aug 11. Hypertens Res. 2011. PMID: 21833000 Clinical Trial.
Tolerability and safety of a calcium channel blocker in comparison with a diuretic in the treatment of elderly patients with hypertension: secondary analysis of the NICS-EH.
Kuwajima I, Kuramoto K, Ogihara T, Iimura O, Abe K, Saruta T, Ishii M, Hiwada K, Fujishima M, Fukiyama K; National Intervention Cooperative Study in Elderly Hypertensives (NICS-EH) Study Group. Kuwajima I, et al. Among authors: fukiyama k. Hypertens Res. 2001 Sep;24(5):475-80. doi: 10.1291/hypres.24.475. Hypertens Res. 2001. PMID: 11675939 Free article. Clinical Trial.
Improvement of accessory symptoms of hypertension by TSUMURA Orengedokuto Extract, a four herbal drugs containing Kampo-Medicine Granules for ethical use: a double-blind, placebo-controlled study.
Arakawa K, Saruta T, Abe K, Iimura O, Ishii M, Ogihara T, Hiwada K, Fukiyama K, Fujishima M, Mizuno Y, Kikuchi T, Takaori S. Arakawa K, et al. Among authors: fukiyama k. Phytomedicine. 2006 Jan;13(1-2):1-10. doi: 10.1016/j.phymed.2004.02.012. Epub 2005 Jul 21. Phytomedicine. 2006. PMID: 16360926 Clinical Trial.
174 results